Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY

touchPODCAST

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three leading experts in melanoma discuss the risk of recurrence in early-stage disease, evaluate the latest data for adjuvant and neoadjuvant therapies, and consider the role of emerging biomarkers for predicting recurrence and guiding treatment decisions.

The experts

• Dr Tina J Hieken, Mayo Clinic, Rochester, MN, USA
• Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
• Dr Teresa Amaral, Tübingen University, Tübingen, Germany

This touchPODCAST is for healthcare professionals outside of the UK only

This activity is funded by an independent medical education grant from Merck & Co., Inc. and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website:
https://touchoncologyime.org/navigating_treatment_choices_in_high-risk_early-stage_melanoma